Friday, July 10, 2026

Drug profile · INN

fosfomycin disodium

fosfomycin disodium (CONTEPO) is an FDA-listed pharmaceutical active ingredient. Route of administration: intravenous. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — fosfomycin disodium
US status
approved
Class
Route
INTRAVENOUS
Patents
0
Programs
2
Data quality
0.84

Quick answer

fosfomycin disodium (CONTEPO) is an FDA-listed pharmaceutical active ingredient. Route of administration: intravenous. Current US regulatory status: approved.

Key facts

INN fosfomycin disodium
Brand CONTEPO
Route INTRAVENOUS
Formulation POWDER

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. FOSFOMYCIN , SULFAMETHOXAZOLE AND TRIMETHOPRIM Phase 3 · Tour Hekla · Benign Prostate Hyperplasia
  2. FOSFOMYCIN Approved · George Institute for · Uncomplicated urinary tract infection (uUTI)

Frequently asked questions

What is fosfomycin disodium?

fosfomycin disodium (CONTEPO) is an FDA-listed pharmaceutical active ingredient. Route of administration: intravenous. Current US regulatory status: approved.

What is the brand name for fosfomycin disodium?

CONTEPO is a marketed brand name for fosfomycin disodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of fosfomycin disodium?

fosfomycin disodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.